A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)

Asthma Clinical Trial

— PILLAR  

Official title:

A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03927820
• Other study ID #: PILLAR
• Status: Active, not recruiting
• Start date: September 9, 2019
• Est. completion date: June 2024

Study information

• Verified date: August 2023
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this study is to assess the impact of pharmacist-led benefits investigations and application of clinical practice guidelines on patient access to inhalers and time to hospital readmission or Emergency Department (ED) visit.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1294
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patient admitted to Vanderbilt University Medical Center (VUMC) (excluding surgery services)
• on a long acting inhaler or prescribed a long acting inhaler during admission.

Exclusion Criteria:

• Diagnosis of cystic fibrosis
• Diagnosis of graft versus host disease (GVHD)
• no medication insurance
• discharge to any post-acute care facility or inpatient hospice
• death during hospitalization

Related Conditions & MeSH terms

• Asthma
• COPD

Intervention

Other:
• Benefits investigation
The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.

Locations

Country	Name	City	State
United States	Vanderbilt Univeristy Medical Center	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to either hospital readmission or ER visit	Combined time (days) to either hospital readmission or emergency department visit after hospitalization (all outcomes measured at 6 months post-discharge with a 3 month interim analysis)	6 months
Secondary	Frequency of ED visit	number of ED visits 6 months post-discharge	6 months
Secondary	frequency of hospital readmissions	number of hospital readmission 6 months post-discharge	6 months
Secondary	time to 1st ED visit (days)	time until the first ED visit post-discharge	6 months
Secondary	time to 1st readmission (days)	time until the first readmission post-discharge	6 months
Secondary	frequency of prescribed inhaler at discharge	number of times the recommended inhaler was prescribed at discharge	6 months
Secondary	frequency of short course prescription of oral steroid	number of oral steroid prescriptions in the 6 months post-discharge	6 months